title: c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma.
abstract: c-Met, a high-affinity receptor for hepatocyte growth factor (HGF), plays a critical role in cancer growth, invasion, and metastasis. Hepatocellular carcinoma (HCC) patients with an active HGF/c-Met signaling pathway have a significantly worse prognosis. Although targeting the HGF/c-Met pathway has been proposed for the treatment of multiple cancers, the effect of c-Met inhibition in HCC remains unclear. The human HCC cell lines Huh7, Hep3B, MHCC97-L, and MHCC97-H were used in this study to investigate the effect of c-Met inhibition using the small molecule selective c-Met tyrosine kinase inhibitor PHA665752. MHCC97-L and MHCC97-H cells demonstrate a mesenchymal phenotype with decreased expression of E-cadherin and increased expression of c-Met, fibronectin, and Zeb2 compared with Huh7 and Hep3B cells, which have an epithelial phenotype. PHA665752 treatment blocked phosphorylation of c-Met and downstream phosphoinositide 3-kinase/Akt and mitogen-activated protein kinase/Erk pathways, inhibited cell proliferation, and induced apoptosis in c-Met-positive MHCC97-L and MHCC97-H cells. In xenograft models, administration of PHA665752 significantly inhibited c-Met-positive MHCC97-L and MHCC97-H tumor growth, and PHA665752-treated tumors demonstrated marked reduction of both c-Met phosphorylation and cell proliferation. c-Met-negative Huh7 and Hep3B cells were not affected by c-Met inhibitor treatment in vitro or in vivo. In addition, c-Met-positive MHCC97-L and MHCC97-H cells demonstrated cancer stem cell-like characteristics, such as resistance to chemotherapy, tumor sphere formation, and increased expression of CD44 and ABCG2, and PHA665752 treatment suppressed tumor sphere formation and inhibited CD44 expression.
  
  
  CONCLUSIONS
  c-Met represents a potential target of personalized treatment for HCC with an active HGF/c-Met pathway.
authors: Department of Pediatrics and Pharmacology, The Pennsylvania State University, College of Medicine, Hershey, PA 17033, USA.
authors: Hanning
authors: H
authors: You
authors: Wei
authors: W
authors: Ding
authors: Hien
authors: H
authors: Dang
authors: Yixing
authors: Y
authors: Jiang
authors: C Bart
authors: CB
authors: Rountree
references: Cell. 1994 Apr 22;77(2):261-71
references: 7513258
references: Cell. 2011 Mar 4;144(5):646-74
references: 21376230
references: Cancer Res. 2003 Nov 1;63(21):7345-55
references: 14612533
references: Nature. 1995 Feb 23;373(6516):702-5
references: 7854453
references: Hepatology. 1997 Mar;25(3):619-23
references: 9049208
references: J Clin Oncol. 2002 Feb 1;20(3):719-26
references: 11821453
references: World J Gastroenterol. 2001 Oct;7(5):630-6
references: 11819844
references: Nat Rev Cancer. 2002 Jun;2(6):442-54
references: 12189386
references: Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11445-50
references: 9326629
references: Cancer Metastasis Rev. 2003 Dec;22(4):309-25
references: 12884908
references: Hepatology. 2009 Apr;49(4):1277-86
references: 19115422
references: Hepatology. 2010 May;51(5):1635-44
references: 20196115
references: Hepatology. 2001 Oct;34(4 Pt 1):688-93
references: 11584364
references: J Biol Chem. 1991 Nov 25;266(33):22087-90
references: 1718989
references: Nat Rev Cancer. 2002 Apr;2(4):289-300
references: 12001990
references: Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4477-82
references: 15070743
references: Cell. 2008 May 16;133(4):704-15
references: 18485877
references: Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2316-21
references: 16461907
references: Science. 1987 Jan 9;235(4785):177-82
references: 3798106
references: J Clin Invest. 2009 Jun;119(6):1420-8
references: 19487818
references: Nature. 1995 Feb 23;373(6516):699-702
references: 7854452
references: Gastroenterology. 2009 Mar;136(3):1012-24
references: 19150350
references: Hepatology. 2009 Nov;50(5):1464-74
references: 19821482
references: Hepatology. 1997 Dec;26(6):1458-66
references: 9397985
references: Stem Cells. 2006 Jan;24(1):23-33
references: 16100005
references: Cancer Lett. 2008 Jul 8;265(2):258-69
references: 18395971
references: J Gastrointest Surg. 2008 Feb;12(2):327-37
references: 17943391
references: Hepatology. 2010 Aug;52(2):506-17
references: 20683950
references: Oncogene. 1995 Jan 19;10(2):237-49
references: 7838524
references: J Clin Invest. 2006 Jun;116(6):1582-95
references: 16710476
references: Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14417-22
references: 9826715
references: J Clin Gastroenterol. 2002 Nov-Dec;35(5 Suppl 2):S72-8
references: 12394209
references: Cancer Res. 2007 Oct 15;67(20):9844-51
references: 17942915
references: Hepatology. 2009 Feb;49(2):491-503
references: 19065669
references: Stem Cells. 2009 Feb;27(2):290-9
references: 19008348
references: Gut. 2010 Jul;59(7):953-62
references: 20442200
references: Hepatology. 2010 Sep;52(3):945-53
references: 20564331
references: Oncogene. 1999 Apr 8;18(14):2343-50
references: 10327054
references: Lancet. 2003 Dec 6;362(9399):1907-17
references: 14667750
references: Nature. 2002 Aug 22;418(6900):823
references: 12192390